…to receive electronic communications from CytomX (via a posting on the Services), and you agree that any such communications satisfy any legal requirement to make such communications in writing. You…
Read MoreBoni V, Fidler MJ, Arkenau HT, et al. Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase 1/2 trial [published online ahead of print,…
Read More…may provide to us through your use of our website located at www.CytomX.com, our social media pages, and any of our other web pages that link to this Privacy Notice…
Read MoreNaing A, Thistlethwaite F, De Vries EG, et al. Journal for ImmunoTherapy of Cancer 2021;9:e002447. doi: 10.1136/jitc-2021-002447…
Read MoreKathy D. Miller, Leisha A. Emens, Sara M. Tolaney, Sara A. Hurvitz, Erika Hamilton, Virginia Paton, Alison Hannah, Valentina Boni. Poster presented at the San Antonio Breast Cancer Symposium®, December…
Read More…by CytomX or CytomX employees may come from similar sounding emails with endings like “@cytomxjobs.com” or “@cytomxtx.com” or even emails ending in common public domain addresses with endings like “@gmail.com,”…
Read More…information related to the CytomX website currently located at http://cytomx2018.wpengine.com/ (the “Website,” and together with any successor URLs, applications and other online services CytomX may offer, the “Services”). By accessing…
Read More